See more : Xiwang Foodstuffs Co.,Ltd. (000639.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Nexalin Technology, Inc. (NXL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nexalin Technology, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Integral Ad Science Holding Corp. (IAS) Income Statement Analysis – Financial Results
- Visa Inc. (3V64.DE) Income Statement Analysis – Financial Results
- Duos Technologies Group, Inc. (DUOT) Income Statement Analysis – Financial Results
- TIS Inc. (TISNF) Income Statement Analysis – Financial Results
- Natoco Co., Ltd. (4627.T) Income Statement Analysis – Financial Results
Nexalin Technology, Inc. (NXL)
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 110.75K | 1.32M | 144.07K | 242.91K | 207.38K |
| Cost of Revenue | 25.69K | 363.21K | 21.44K | 29.04K | 218.21K |
| Gross Profit | 85.06K | 958.15K | 122.62K | 213.88K | -10.83K |
| Gross Profit Ratio | 76.80% | 72.51% | 85.12% | 88.05% | -5.22% |
| Research & Development | 1.92M | 511.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 5.78M | 2.79M | 6.14M | 3.47M | 78.13K |
| Selling & Marketing | 0.00 | 886.41K | 35.49K | 10.71K | 1.38M |
| SG&A | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Other Expenses | 0.00 | 171.68K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Cost & Expenses | 5.81M | 3.15M | 6.16M | 3.50M | 1.67M |
| Interest Income | 0.00 | 59.38K | 82.32K | 78.68K | 80.99K |
| Interest Expense | 38.84K | 59.38K | 82.32K | 78.68K | 80.99K |
| Depreciation & Amortization | 4.25K | 5.72K | 537.00 | 429.00 | 535.00 |
| EBITDA | -5.69M | -1.83M | -6.00M | -3.32M | -1.47M |
| EBITDA Ratio | -5,139.63% | -125.69% | -4,177.33% | -1,341.21% | -706.72% |
| Operating Income | -5.70M | -1.83M | -6.02M | -3.26M | -1.47M |
| Operating Income Ratio | -5,143.48% | -138.72% | -4,177.70% | -1,341.38% | -706.98% |
| Total Other Income/Expenses | 1.05M | 135.22K | -59.40K | -145.08K | -3.56M |
| Income Before Tax | -4.65M | -1.70M | -6.08M | -3.40M | -5.02M |
| Income Before Tax Ratio | -4,197.56% | -128.49% | -4,218.93% | -1,401.11% | -2,421.22% |
| Income Tax Expense | 0.00 | 228.00K | 82.32K | 78.68K | 5.00 |
| Net Income | -4.65M | -1.93M | -6.16M | -3.48M | -5.02M |
| Net Income Ratio | -4,197.56% | -145.75% | -4,276.07% | -1,433.50% | -2,421.22% |
| EPS | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| EPS Diluted | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| Weighted Avg Shares Out | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
| Weighted Avg Shares Out (Dil) | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placebo Data published in Journal of Psychiatric Research suggests that the Gen-2 tACS device may have the potential to reduce chronic...
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
Company's International Reach Expanding with Latest Regulatory Approval Company's International Reach Expanding with Latest Regulatory Approval
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company's non-invasive,...
Nexalin Technology Unveils Next-Generation HALO™ Clarity
A new neurostimulation device to combat the growing global mental health epidemic Designed for drug-free treatment of mental health conditions from the privacy of one's home with virtual monitoring by a physician Photo: HALO™ Clarity headset HOUSTON, TEXAS, Jan. 11,...
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
Results published in General Psychiatry, a leading peer-reviewed journal Results published in General Psychiatry, a leading peer-reviewed journal
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
HOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory Board ( “Advisory Board”) to support its non-invasive, frequency-based, deep-brain stimulation devices...
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures
Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health disease Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device...
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA)...
Nexalin's CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participating in a live interview with the “Big Biz Show,” an Emmy...
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the formation of a new division, to be called “Nexalin America,” aimed at fostering relationships within the U.S. Department of Defense, U.S....
Source: https://incomestatements.info
Category: Stock Reports